natgillin/translations-raw huggingface dataset:
Method for the immunological determination of an antibody against the amyloid B peptide in a sample using an immunoassay employing an antibody obtained from cell line DSM ACC2939, wherein the immunoassay comprises a capture antibody, a tracer antibody and a detection antibody, wherein said capture antibody is a biotinylated anti-idiotype antibody against an antibody against the amyloid B peptide obtained from cell line DSM ACC2939 conjugated to a solid phase via streptavidin, said tracer antibody is an anti-idiotype antibody against an antibody against the amyloid B peptide obtained from cell line DSM ACC2939 conjugated to digoxygenin as detectable label, and said detection antibody is an antibody against digoxygenin conjugated to a peroxidase. 
Postupak za imunološko određivanje protutijela za amiloid-B-peptid, naznačen time, da se provodi u uzorku uporabom imunološke analize koja se primjenjuje na protutijelu koje se dobiva iz stanične linije DSM ACC2939, pri čemu imunološka analiza obuhvaća protutijelo za hvatanje, protutijelo za traganje i protutijelo za otkrivanje, dok spomenuto protutijelo za hvatanje je biotinilirano anti-idiotipično protutijelo koje je protiv protutijela za amiloid-B-peptid, dobiveno iz stanične linije DSM ACC2939, i konjugirano preko streptavidina na krutu fazu, gdje protutijelo za traganje je anti-idiotipično protutijelo koje je protiv protutijela za amiloid-B-peptid, dobiveno iz stanične linije DSM ACC2939, i konjugirano na digoksigenin koji služi kao oznaka koja se može otkrivati, te spomenuto protutijelo za otkrivanje je protutijelo protiv digoksigenina, konjugirano na peroksidazu.
Combining this with the expression (32) representing Ee(t); 
(32) Datum podnošenja prve prijave: 08.04.2009.
The reaction was stirred at ambient temperature for 16 h at which time the mixture was diluted with EtOAc (75 mL) and filtered. 
Reakcija je miješana na sobnoj temperaturi tijekom 16 sati nakon čega je smjesa razrijeđena sa ELOAc (75 mL) i filtrirana.
is selected from the group consisting of optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocyclyl; 
je izabran iz grupe koja se sastoji od izborno supstituiranog arila, izborno supstituiranog heteroarila, izborno supstituiranog cikloalkila, izborno supstituiranog heterociklila;
The invention also relates to nucleic acids and genetic products which are expressed in association with a tumor cell. 
(54) Naziv izuma: GENETSKI PROIZVODI KOJI SU DIFERENCIJALNO IZRAŽENI U TUMORIMA I NJIHOVA
wherein the boronic ester compound of formula (I) constitutes at least about 70% w/w of the composition. 
Kompozicija prema patentnom zahtjevu 20, gdje spoj ester organoborne kiseline formule (7) čini najmanje 70% tož./tež. kompozicije.
The XRPD spectra of crystalline pure monoclinic form and pure orthorhombic form are depicted in Figure 1. 
XRPD spektri kristalnog čistog monoklinskog oblika i čistog ortorombskog oblika prikazani su na Slici 1.
A transdermal delivery device comprising: a polymer matrix layer comprising an opioid agonist with intermixed microspheres comprising opioid antagonist, wherein the opioid antagonist is non-releasable when the transdermal delivery device is applied topically and intact, and wherein the microspheres are in a mean size of from 1 to 300 µm in diameter. 
Uređaj za transdermalno davanje koji sadrži: sloj polimerne matrice koji sadrži opioidni agonist s međusobno izmiješanim mikrosferama koje sadrže opioidni antagonist, te naznačen time da su mikrosfere u promjeru srednje veličine 1 do 500 µm.
A composition for use according to any one of the preceding claims, wherein at least one of a social domain, a communication domain and a cognitive domain are improved in the human following treatment with the gamma-aminobutyric acid agonist. 
Pripravak namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što dolazi do poboljšanja najmanje jednog od socijalnih vještina, komunikacijskih vještina i kognitivnih vještina kod osobe nakon liječenja agonistom Y-aminomaslačne kiseline.
The communication device according to claim 1 wherein Localized Virtual Resource Blocks (LVRBs), which are mapped to PRBs, are allocated to the terminal in units of RBGs. 
Integrirani krug sukladno jednom od zahtjeva 1 do 7, naznačen time da su u drugoj dodjeli, PRB-ovi, na koje DVRB-ovi nisu mapirani, dodijeljeni uređaju mobilnoj stanici.
The compound or composition of claim 6, wherein the fibrosis is kidney fibrosis. 
Spoj ili pripravak prema zahtjevu 6, naznačen time da fibroza je fibroza bubrega.
The concentrator according to claim 17, further configured to transmit values indicating storage locations to the selected remote meter requesting transmission of utility consumption related data stored in the storage locations indicated by said values. The concentrator according to claim 17, further configured to determine, on the basis of said status data, whether sufficient utility consumption related data are stored at the selected remote meter. The concentrator according to claim 17, further configured to determine whether the selected remote meter is enabled to transmit the amount of utility consumption related data to said concentrator. 
Sabirnik prema bilo kojem od patentnih zahtjeva 19 do 24, nadalje prilagođen za provođenje operacija utvrđivanja na temelju navedenih trenutnih podataka je li dovoljna količina periodički izmjerenih i pohranjenih podataka vezanih uz potrošnju pohranjena na daljinskom brojaču (RM). Sabirnik prema bilo kojem od patentnih zahtjeva 19 do 24, nadalje prilagođen za provođenje operacija utvrđivanja je li daljinskom brojaču (RM) omogućeno provođenje operacija prijenosa količine (L) periodički izmjerenih i pohranjenih podataka vezanih uz potrošnju (MV1, MV2...
The method of claim 26 wherein the antibody is a HER2 antibody selected from the group consisting of trastuzumab and pertuzumab. 
HER2-protutijelo odabrano iz skupine koja se sastoji od trastuzumaba i pertuzumaba; CD20-protutijelo koje je rituksimab;
The slurry of claim 1 further comprising at least one of the group consisting of starches, foaming agents, set accelerators, set retarders, biocides, dispersants, fibers or strength enhancers. 
Gusta smjesa iz patentnog zahtjeva 1 koja dalje sadrži barem jednu grupu koja se sastoji od škroba, pjenušavih agenasa, seta akceleratora, seta usporivača, biocida, raspršivača, vlakana ili pojačivača snage.
wherein the intra prediction unit (150) includes: a prediction mode determining unit (154) configured to determine the intra prediction mode of the current prediction block; and 
Metoda za uspostavljanje unutarokovirnog načina predviđanja, sadrži: uspostavljanje prvog unutarokovirnog načina predviđanja grupnog indikatora i indeksa načina predviđanja trenutne predikcijske jedinice;
providing a DIGRA, or a pharmaceutically acceptable salt thereof; and combining said DIGRA, or pharmaceutically acceptable salt thereof with a pharmaceutically acceptable carrier; wherein the DIGRA comprises a compound having Formula I wherein A comprises a dihydrobenzofuranyl group substituted with a halogen atom; Q comprises a quinolinyl or isoquinolinyl group substituted with a C1-C10 alkyl group; R1 and R2 are independently selected from the group consisting of unsubstituted and substituted C1-C5 alkyl groups; B is a C1-C3 alkylene group; D is the -NH- group; E is the hydroxy group; and R3 comprises a completely halogenated C1-C10 alkyl group. 
(a) pružanje DIGRA-e, ili njegove farmaceutski prihvatljive soli; 1 (b) kombiniranje spomenutog DIGRA, ili njegove farmaceutski prihvatljive soli sa farmaceutski prihvatljivim nosačem; pri čemu DIGRA sadrži spoj sa formulom I gdje A sadrži dihidrobenzofuranil skupinu supstituiranu sa halogenim atomom; Q sadrži kvinolinil ili izokvinolinil skupinu supstituiranu sa Cy-Cyo alkil skupinom; R! i RŽ su nezavisno izabrani iz skupine koja sadrži nesupstituiraneo i supstituirane C;-C; alkil skupine; B je C;-C, alkilen skupina; D je skupina; E je hidroksi skupina; te R? sadrži potpuno halogeniranu C;-C;9 alkil skupinu.
The antibody for use according to claim 27, the use according to claim 29 or the method according to claim 31, wherein the cancer is selected from the group consisting of breast cancer, prostate cancer, bone cancer, colorectal cancer, leukaemia, lymphoma, skin cancer, esophageal cancer, gastric cancer, astrocytic cancer, endometrial cancer, cervical cancer, bladder cancer, renal cancer, lung cancer, liver cancer, thyroid cancer, head and neck cancer, pancreatic cancer and ovarian cancer. 
Antitijelo za upotrebu prema patentnom zahtjevu 11 naznačeno time da je rak odabran iz skupine koja se sastoji od raka dojke, raka prostate, raka kostiju, kolorektalnog raka, leukemije, limfoma, raka kože, raka jednjaka, raka želuca, astrocitnog raka, raka endometrijuma, raka vrata materice, raka mokraćnog mjehura, raka bubrega, raka pluća, raka jetre, raka štitnjače, raka glave 1 vrata, raka gušterače i raka jajnika.
wherein said hydroxy-containing polymer is a combination of polyvinyl alcohol and at least one selected from the group consisting of starch, modified starch and a sugar. 
HR P20141042 T1 pri čemu je spomenuti hidroksi-polimer kombinacija polivinil-alkohola i najmanje jednog koji je izdvojen iz grupe, koji se sastoji od škroba, modificiranog škroba 1 šećera.
The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein: Ring A is an unsaturated monocyclic heterocyclic ring which may optionally be substituted by a halogen atom, a C1-6 alkyl group, a halo-C1-6 alkyl group, a C1-6 alkoxy group, or an oxo group, and 
Spoj u skladu s patentnim zahtjevom 1, ili njegova farmaceutski prihvatljiva sol, naznačen time što svaki od R1a, R2a, R3a, R1b, R2b i R3b je neovisno atom vodika, atom halogena, C1-6 alkilna skupina, halogen-C1-6 alkilna skupina, C1-6 alkoksi skupina ili fenilna skupina; i
A compound of formula (I) a stereo-isomeric form, a pharmaceutically acceptable salt, solvate or polymorph thereof comprising a mono- or di-substituted indole group; said compound is selected from the group wherein: 
PATENTNI ZAHTJEVI 1. = Spoj formule (I) OCH 5 njegov stereoizomerni oblik, farmaceutski prihvatljiva sol, solvat ili polimorf koji sadrže mono- ili di-supstituiranu indolnu skupinu; navedeni spoj je odabran iz skupine pri čemu:
This server (14) sends an electronic mail to the transmitting user (1) including the certificate (4). FIG. 
- < slanje elektronskog dokumenta s odlaznog poslužitelja (14) prema trećoj strani zbog izvršavanja drugog elektronskog potpisa, 1
A fluid distribution system according to claim 13, said fluid distribution system being arranged to supply fluid to a load, said fluid distribution system comprising: said load, a control unit, 
Sustav (1000a) za distribuciju fluida prema zahtjevu 13, pri čemu je navedeni Sustav (10004) za distribuciju fluida prilagođen za napajanje opterećenja fluidom, navedeni Sustav za distribuciju fluida sadrži:
The rat LH Time-Resolved Immuno Fluorometric Assay (TR-IFMA) has been developed in house using home made reagents, a monoclonal catching antibody directed against the B-subunit of human chorion gonadotrophin (hCG, which cross reacts with rat B-subunit) and a biotin labelled detecting antibody (rabbit polyclonal antibody directed against the alfa-subunit of recombinant rat LH). 
U našoj kući razvijeno je Vremenski ovisno imunofluorimetrijsko ispitivanje štakorskog LH (TR-IFMA), pomoću reagensa iz kućne radinosti, monoklonskog uhvatnog protutijela protiv B-podjedinice ljudskog korionskog gonadotrofina (hCG, koji ukriženo reagira sa štakorskom B-podjedinicom) i biotinom obilježenog detekcijskog protutijela (kunićje poliklonsko protutijelo protiv a-podjedinice rekombinantnog štakorskog LH).
The aqueous formulation for use of claim 18 wherein said pharmaceutical composition further comprises excipients selected from the group consisting of zinc, m-cresol, glycerol, polysorbate 20 and sodium. 
Vodena formulacija za uporabu prema zahtjevu 19 naznačena time da navedeni farmaceutski pripravak nadalje sadrži ekscipijente odabrane iz skupine koju čine cink, m-krezol, glicerol, polisorbat 20 i natrij.
a mutated spr gene encoding an spr protein whose wild-type sequence is shown in SEQ ID NO: 24 comprising a mutation affecting the amino acid C94; and wherein said gram-negative bacterial cell is selected from E. coli strains K12 and W3110, and wherein the bacterial cell is isogenic to said strains except for the recombinant polynucleotide encoding DsbC, the one or more polynucleotides encoding an antibody or an antigen binding fragment thereof specifically binding to CD154 and the mutated Tsp gene and the mutated spr gene. 
mutirani spr gen koji kodira spr protein čija je sekvenca divljeg tipa prikazana u SEK ID BR: 24 uključujući mutaciju koja utječe na aminokiselinu C94; i pri čemu je navedena gram-negativna bakterijska stanica izabrana od sojeva E. coli K12 i W3110, i pri čemu je bakterijska stanica izogen za navedene sojeve, osim za rekombinantni polinukleotid koji kodira DsbC, jedan ili više polinukleotida koji kodiraju antitijelo ili antigen vezujući fragment od njih koji se specifično veže za CD154 i mutirani Tsp gen i mutirani spr gen.
Another aspect is a pharmaceutical composition comprising a double-stranded nucleic acid molecule and drug carrier comprising a mixture of a retinoid and a lipid, wherein the double-stranded oligonucleotide compound comprising the structure (A1): 
(i) dvolančanu molekulu nukleinske kiseline i nosač lijekova, koji sadrži smjesu retinoida 1 lipida, gdje dvolančana molekula nukleinske kiseline ima strukturu (A1):
In this way, all the program code which refers to the communication with the management program 17 is grouped together. 
Na taj su način svi programski kodovi koji se odnose na komuniciranje s programom za rukovođenje 17 skupljeni zajedno.
A composition according to claim 1, wherein component (A) is 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and component (B) is selected from azoxystrobin and picoxystrobin. 
Pripravak prema zahtjevu 1, naznačen time da je komponenta (A) 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-iljamid i komponenta (B) je odabrana od azoksistrobina i pikoksistrobina.
1 g disclose the cigarette box in axonometric view, in a variety of realizations, with the front wall and the hinged lid open. 
If, SI. 1g otkrivaju aksonometrijski pogled na razne izvedbe kutije za cigarete, s otvorenim prednjim zidom i preklopnim poklopcem.
The compound of Claim 1 or a pharmaceutically acceptable salt thereof, for use in treating a condition mediated by dipeptidyl peptidase-IV in a mammal. 
Spoj u skladu s patentnim zahtjevom 1 ili njegova farmaceutski prihvatljiva sol, namijenjen upotrebi u liječenju stanja posredovanog dipeptidil-peptidazom-IV kod sisavca.
separating the A9-tetrahydrocannabinol from the resulting phase containing the A9-tetrahydrocannabinol; and 
razdvajanje A9-tertahidrokanabinola iz nastale faze koja sadrži A9-tertahidrokanabinol; i
The transfer vehicle of claim 2, wherein the protein is an enzyme. 
Nosač transfera prema zahtjevu 2, naznačen time što je protein enzim.
A compound as claimed in claims 1 or 2, wherein R1 and R2 represent independently hydrogen, or C1-6 alkyl with straight or branched chain optionally substituted with C1-6 alkoxycarbonyl, or phenyl or R1 and R2 form an optionally by C1-6 alkyl or hydroxy substituted pyrrolidine, piperazine, piperidine or morpholine ring; 
Spoj prema zahtjevima 1 ili 2, naznačen time, da i R2 predstavljaju neovisno vodik, ili C1-6 alkil s ravnim ili razgranatim lancem opcijski supstituiran s C1-6 alkoksikarbonilom, ili fenilom, ili
A composition according to claim 1 wherein the matrix comprises a sugar and/or sugar alcohol and/or cyclodextrin selected from the group consisting of sucrose, lactose, fructose, maltose, raffinose, sorbitol, lactitol, mannitol, maltitol, erythritol, inositol, trehalose, isomalt, inulin, maltodextrin, B-cyclodextrin, hydroxypropyl-B-cyclodextrin and sulfobutyl ether cyclodextrin. 
Pripravak prema zahtjevu 1 naznačen time da matrica sadrži šećer i/ili šećerni alkohol i/ili ciklodekstrin odabran iz skupine koju čine sukroza, laktoza, fruktoza, maltoza, rafinoza, sorbitol, laktitol, manitol, maltitol, eritritol, inositol, trehaloza, izomalt, inulin, maltodekstrin, B-ciklodekstrin, hidroksipropil-B-ciklodekstrin i sulfobutil eter ciklodekstrin.
The carboxylic acid group and the hydroxyl group at the δ position are prone to lactonize. 
Karboksilna kiselinska skupina i hidroksilna skupina na položaju & teže stvaranju laktona.
The micropellets were subjected to the screening procedure as described above and the particle size distribution was summarized in Table III. 
Mikropelete se podvrgnu postupku sortiranja kako je to već gore navedeno i razdioba veličine čestica je prikazana u Tabeli III.
or a salt of this compound. 
ili sol toga spoja.
operating an electromagnetic brake, under the condition that the inverter motor allows the top mold mounting member to perform retained operation to stop in the elevating direction, to fix the ball screw shaft, and thereafter powering off the inverter motor. 
upravljanje elektromagnetskom kočnicom (57) nezavisno od upravljanja tim inverter motorom, pod uvjetom da inverter motor omogućava dijelu za namještanje gornjeg kalupa da se zadrži u radu u zaustavljenom dignutom smjeru, da fiksira kuglastu navojnu šipku, i zatim isključivanje inverter motora; i provođenje kontrole rada motora za uključivanje i isključivanje tog inverter motora preko kontrole invertera.
Electric vehicle thermal management system 
SUSTAV DISIPACIJE TOPLINE ELEKTRIČNOG VOZILA
a single-molecule DNA-targeting RNA, or a nucleic acid comprising a nucleotide sequence encoding said single-molecule DNA-targeting RNA, wherein the single-molecule DNA-targeting RNA comprises: a DNA-targeting segment comprising a nucleotide sequence that is complementary to a sequence in a target DNA, and 
RNK jednostruke molekule koja cilja na DNK, ili nukleinska kiselina koja obuhvaća nukleotidnu sekvencu koja kodira navedenu RNK jednostruke molekule koja cilja na DNK, pri čemu RNK jednostruke molekule koja cilja na DNK, obuhvaća sljedeće: segment koji cilja na DNK, te koji obuhvaća nukleotidnu sekvencu koja je komplementarna sa sekvencom u ciljanoj DNK; i
The device according to claim 1, where the pharmaceutical ingredients are encapsulated prior to incorporation into the device. 
Naprava prema bilo kojem od zahtjeva 1-12, naznačena time što su farmaceutski sastojci inkapsulirani prije ugradnje u napravu.
or wherein R4 is an alkylaryl optionally substituted by one or more substituents independently selected from halogen, aryloxy, aryl, alkylamino, dialkylamino, C1-6 alkyl, carboxylic acid, carboxylic ester, carboxylic amide, sulfonamide, nitrile, or C1-6alkoxy. 
je alkilaril proizvoljno supstituiran s jednim ili više supstituenata koji se neovisno biraju iz niza koji sadrži halogen, ariloksi, aril, alkilamino, dialkilamino, C1-6 alkil, karboksilnu kiselinu, karboksilni ester, karboksilni amid, sulfonamid, nitril, ili C1-6alkoksi.
The invention relates to compounds of the formula I in which 
PATENTNI ZAHTJEVI Spojevi s formulom I naznačeni time da
preparing a solution of the compound of formula (II) below and an organic or inorganic base in a polar aprotic solvent, and 
pripravljanje otopine spoja formule (II) i organske ili anorganske baze u polarnom aprotičnom otapalu, te [image]
The reaction was allowed to warm to room temperature at which stirring was continued for 2 h. 
Reakcijsku smjesu ostavi se da sc zagrije na sobnu temperaturu, a zatim sc s miješanjem nastavi još 2 sata.
The catheter as claimed in any preceding claim, wherein the distal portion of said tube has a durometer of 80 to 90 Shore A, and the proximal portion of said tube has a durometer of 50 to 60 Shore A. 
Kateter prema bilo kojem od prethodnih zahtjeva, pri čemu zadnji dio spomenute cijevi ima stupanj tvrdoće od 80 do 90 Å ora A, dok prednji dio spomenute cijevi ima stupanj tvrdoće od 50 do 60 Å ora A.
or R1 is a substituted carbocyclyl group wherein the substitutent is on the same atom which links the carbocyclyl group to the remainder of the molecule; 
ili je supstituirana karbociklilna skupina, gdje je supstitutent na istom atomu koji povezuje karbociklilnu skupinu s ostatkom molekule;
The protecting group P1 is removed by standard procedures to provide an intermediate of formula (III). 
(a) izlaganje spoja formule (III) reakciji: iv sr R 1 OSI OI
In spite of a shorter acquisition phase, the “natural” forgetting is significantly reduced by 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine monohydrochloride at the dose of 15 mg/kg and by tacrine without change in the tacrine effect when the acetylcholinesterase inhibitor is associated together with the H3 receptors antagonist/inverse agonist. 
Usprkos kraćoj akvizicijskoj fazi,, prirodno" je zaboravljanje značajno smanjeno uz 1-[3-[3-(4-klorfeniDpropoksilpropil]-piperidin monoklorid pri dozi od 15 mg/kg i uz takrin, bez promjene učinka takrina kada je inhibitor acetilkolinesteraze vezan s antagonistom/inverznim agonistom H3 receptora.
represents a hydrogen atom; and 
R*predstavlja atom vodika; i
Also particular preference is given to a pharmaceutical composition comprising the p-toluene-sulfonic acid salt of 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-phenoxy}-pyridine-2-carboxylic acid methyl amide in a portion of at least 75%, microcrystalline cellulose as a filler in a portion of from 3 to 20%, croscarmellose sodium as a disintegrant in a portion of from 5 to 12%, hypromellose as a binder in a portion of from 0.5 to 8%, magnesium stearate as a lubricant in a portion of from 0.2 to 8% and sodium lauryl sulfate as a surfactant in a portion of from 0.1 to 2% by weight of the composition. 
Farmaceutski pripravak prema zahtjevu 2 naznačen time da je mikrokristalinična celuloza kao punilo u udjelu od 3 do 20 %, kroskarmeloza natrij kao sredstvo za raspadanje u udjelu od 5 do 12 %, hipromelozu kao vezivo u udjelu od 0.5 do 8 %, magnezijev stearat kao lubrikant u udjelu od 0.2 do 8 % i natrijev lauril sulfat kao surfaktant u udjelu od 0.1 do 2 % težinski pripravka.
Furthermore, the container 151 is provided frontally with a cross-shaped shank 153 for coupling with an elongated handle 154, the latter being preferably made of a thermosetting material. 
Nadalje, spremnik 151 ima s prednje strane križni shank 153, za povezivanje s izduljenom drškom 154, gdje je potonja po mogućnosti načinjena od termoreaktivnog materijala.
a transfer vehicle and at least one mRNA molecule encoding said protein, the transfer vehicle comprising one or more cationic lipid(s), one or more non-cationic lipid(s), and one or more PEG- modified lipid(s), wherein the transfer vehicle is a liposome and the size of the transfer vehicle is less than 100 nm, 
nosač transfera i najmanje jednu molekulu iRNK koja kodira navedeni protein, nosač transfera koji sadrži jedan ili više kationskih lipida, jedan ili više nekationskih lipida i jedan ili više lipida modificiranih s PEG, pri čemu je nosač transfera liposom, a veličina nosača transfera je manja od 100 nm, i pri čemu se farmaceutski pripravak poželjno nakon primjene subjektu distribuira u stanice jetre, a kodirani protein se eksprimira u stanicama jetre subjekta.
A glassy lozenge according to claim 2 wherein 50-90 wt % of component (ii) consists of: 
Tableta-pastila prema patentnom zahtjevu 2, naznačena time što se 50-90 mas.% komponente (11) sastoji od:
a haematological disorder; and 
(c) hematološkog poremećaja; i
and R6 are independently a hydrogen atom, a halogen atom, a lower alkyl group, a halo-lower alkyl group, a hydroxy-lower alkyl group, a lower alkoxy group, a lower alkanoyl group, a hydroxy-lower alkylamino group, a carbamoyl group or a hydroxy-lower alkylcarbamoyl group; 
i R6 su nezavisno atom vodika, halogen atom, niža alkilna skupina, halo-niža alkilna skupina, hidroksi-niža alkilna skupina, niža alkoksi skupina, niža alkanoil skupina, hidroksi-niža alkilamino skupina, karbamoil skupina ili hidroksi-niža alkilkarbamoil skupina;